Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab and Durvalumab in Resectable Colorectal Cancer Liver Metastases
NCT02754856Phase 1Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2016
- Primary completion
- Jan 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tremelimumab and durvalumab in colorectal cancer (CRC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Post-operative Toxicity at 3 years and Feasibility and Safety in the Conduct of the Trial at 3 years. Started Aug 2016; status: completed.
02
Drugs
tremelimumabdurvalumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02754856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02754856.